Journal
PHARMACOGENOMICS JOURNAL
Volume 9, Issue 5, Pages 311-318Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2009.24
Keywords
schizophrenia; risperidone; single nucleotide polymorphism; SNP; pharmacogenomics; atypical antipsychotic
Categories
Ask authors/readers for more resources
Clinical trial data were evaluated for the association between 22 single-nucleotide polymorphisms (SNPs) and response in acutely ill patients diagnosed with schizophrenia, schizoaffective disorder or schizophreniform disorder, who were treated with oral risperidone. All patients in the exploratory (78 African Americans) and validation (65 whites) data sets received risperidone 2-6 mg per day over 2-12 weeks. Two SNPs were found to have significant associations with response to risperidone over 2-12 weeks in both African-American and white patients and had a consistent direction of effect in both cohorts. Metabotropic glutamate receptor (GRM3) SNP, rs724226, was associated with a change in the positive and negative syndrome scale (PANSS) total response. Catechol-O-methyltransferase (COMT) SNP, rs165599, was moderately associated with a change in the PANSS Negative score. The greater prevalence of poor-responder GRM3 and COMT alleles in white versus African-American patients might have a clinical significance in evaluating the ethnic-specific response to risperidone. The Pharmacogenomics Journal (2009) 9, 311-318; doi:10.1038/tpj.2009.24; published online 19 May 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available